Safety profile of two novel antiepileptic agents approved for the treatment of refractory partial seizures: Ezogabine (retigabine) and perampanel

Expert Opinion on Drug Safety

Volumn 12, Issue 6, 2013, Pages 847-855

  Faulkner, Michele A ^a   Burke, Rachel A ^b  

^a CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CREIGHTON UNIVERSITY   (United States)

Author keywords

AMPA; Ezogabine; Glutamate; Partial seizures; Perampanel; Potassium channels; Retigabine; Urinary retention

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CARBAMAZEPINE; CREATINE KINASE; HYPERICUM PERFORATUM EXTRACT; KETOCONAZOLE; LAMOTRIGINE; MIDAZOLAM; OXCARBAZEPINE; PERAMPANEL; PHENYTOIN; RETIGABINE; RIFAMPICIN; TOPIRAMATE; VOLTAGE GATED POTASSIUM CHANNEL;

ABNORMAL THINKING; AGGRESSION; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMNESIA; ANGER; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; ATAXIA; BLOOD PRESSURE; CENTRAL NERVOUS SYSTEM; CONFUSION; CONVERSION DISORDER; CREATINE KINASE BLOOD LEVEL; DIZZINESS; DRUG DEPENDENCE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EXPOSURE; DRUG MECHANISM; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; EUPHORIA; EYE COLOR; FATIGUE; FOCAL EPILEPSY; GAIT DISORDER; HALLUCINATION; HEADACHE; HOMICIDE; HOSTILITY; HUMAN; IRRITABILITY; NEPHROLITHIASIS; OUTCOME ASSESSMENT; PATIENT COUNSELING; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PSYCHOSIS; QT PROLONGATION; RECOMMENDED DRUG DOSE; RESIDUAL VOLUME; RETINA DYSTROPHY; REVIEW; SIDE EFFECT; SKIN DISCOLORATION; SOMNOLENCE; SPEECH DISORDER; STONE FORMATION; SUICIDAL IDEATION; TREMOR; URINE RETENTION; VERTIGO; VISUAL ACUITY; WEIGHT GAIN;

ANTICONVULSANTS; CARBAMATES; DRUG MONITORING; DRUG RESISTANCE; EPILEPSY, COMPLEX PARTIAL; HUMANS; PATIENT SELECTION; PHENYLENEDIAMINES; POTASSIUM CHANNELS, VOLTAGE-GATED; PYRIDONES; RECEPTORS, AMPA;

EID: 84886636082     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2013.823399     Document Type: Review

References (42)

1. Neligan A, Hauser WA, Sander JW. The epidemiology of the epilepsies. Handb Clin Neurol 2012;107:113-33
2. Tolman JA, Faulkner MA. Treatment options for refractory and difficult to treat seizures: Focus on vigabatrin. Ther Clin Risk Manag 2011;7:367-75
3. Faught E. Ezogabine: A new angle on potassium gates. Epilepsy Curr 2011;11:75-8
4. Brodie MJ, Lerche H, Gil-Nagel A, et al. Efficacy and safety of adjunctive ezogabine (retigabine) in refractory partial epilepsy. Neurology 2010;75:1817-24
5. Biervert C, Schroeder BC, Kubisch C, et al. A potassium channel mutation in neonatal human epilepsy. Science 1998;279:403-6
6. Charlier C, Singh NA, Ryan SG, et al. A pore mutation in a novel KQT-like potassium channel gene in an idiopathic epilepsy family [abstract]. Nat Genet 1998;18:53
7. Singh NA, Charlier C, Stauffer D, et al. A novel potassium channel gene, KCNQ2, is mutated in an inherited epilepsy of newborns [abstract]. Nat Genet 1998;18:25-9
8. Gao Z, Zhang T, Wu M, et al. Isoform-specific prolongation of Kv7 (KCNQ) potassium channel opening mediated by new molecular determinants for drug-channel interactions. J Biol Chem 2010;285:28322-32
9. Porter RJ, Partiot A, Sachdeo R, et al. Randomized, multicenter, dose-ranging trial of retigabine for partial onset seizures. Neurology 2007;68:1197-204
10. French JA, Abou-Khalil BW, Leroy RF, et al. Randomized, double-blind, placebo-controlled trial of ezogabine (retigabine) in partial epilepsy. Neurology 2011;76:1555-63
11. Gil-Nagel A, Brodie MJ, Leroy R, et al. Safety and efficacy of ezogabine (retigabine) in adults with refractory partial-onset seizures: Interim results from two ongoing open-label studies. Epilepsy Res 2012;102:117-21
12. GlaxoSmithKline. Ezogabine (Potiga package insert. Research Triangle Park, NC: 2011
13. Amabile CM, Vasudevan A. Ezogabine: A novel antiepileptic for adjunctive treatment of partial-onset seizures. Pharmacotherapy 2013;33:187-94
14. Mohanraj R, Brodie MJ. Measuring the efficacy of antiepileptic drugs. Seizure 2003;12:413-43
15. Anderson KE, Arner A. Urinary bladder contraction and relaxation: Physiology and pathophysiology. Physiol Rev 2004;84:935-86
16. Chen M, kellett WF, Petkov GV. Voltage-gated K(+) channels sensitive to stromatoxin-1 regulate myogenic and neurogenic contractions of rat urinary bladder smooth muscle. Am J Physiol Regul Inter Comp Physiol 2010;299:R177-84
17. Brickel N, Gandhi P, VanLandingham K, et al. The urinary safety profile and secondary renal effects of retigabine (ezogabine): A first-in-class antiepileptic drug that targets KCNQ (Kv7) potassium channels. Epilepsia 2012;53:606-12
18. Rode F, Svalo J, Sheykhzade M, et al. Functional effects of the KCNQ modulators retigabine and XE991 in the rat urinary bladder. Eur J Pharmacol 2010;638:121-7
19. Streng T, Chrisoph T, Andersson KE. Urodynamic effects of the K+ channel (KCNQ) opener retigabine in freely moving, conscious rats. J urol 2004;172:2054-8
20. Brickel N, Hammond J, DeRossett S. Pharmacological effects of retigabine on bladder function: Results from phase 2/ 3 studies [abstract]. American Epilepsy Society Annual Meeting; 2010. Available from: Http://www.aesnet. org/go/publications/aes-abstracts/ abstract-search?mode=display&sy= 2010&sb=all&startrow=941&id=12472 [Last accessed 26 April 2013]
21. FDA Drug Safety Communication: Anti-seizure drug Potiga (ezogabine) linked to retinal abnormalities and blue skin discoloration. Available from: Http:// www.fda.gov/Drugs/DrugSafety/ ucm349538.htm [Last accessed 10 May 2013]
22. Tompson DJ, van Landingham KE. The effects of retigabine on the pharmacokinetic of concomitantly administered antiepileptic drugs [abstract 187]. 9th Eur Congr Epileptology; 2010
23. Hermann R, Knebel NG, Niebch G, et al. Pharmacokinetic interaction between lamotrigine and retigabine in healthy subjects. Eur J Clin Pharmacol 2003;58:795-802
24. Weisenbert JLZ, Wong M. Profile of ezogabine (retigabine) and its potential as an adjunctive treatment for patients with partial-onset seizures. Neuropsychiatr Dis Treat 2011;7:409-14
25. Ferron GM, Paul J, Richards L, et al. Retigabine does not alter the pharmacokinetics of a low dose oral contraceptive in women [abstract]. Neurology 2001;56(Suppl 3): Abstract P.05.052
26. Ferron GM, Patat A, Parks V, et al. Lack of pharmacokinetic interaction between retigabine and pehnobarbitone at steady-state in healthy subjects. Br J Clin Pharmacol 2003;56:39-45
27. Department of Justice. DEA 21 CFR part 1308. Schedules of controlled substances: Placement of ezogabine into schedule V. Available from: Http://www. regulations.gov/#!documentDetail; D=DEA-2011-0013-0001 [Last accessed 7 May 2013]
28. Takagaki G. The dawn of excitatory amino acid research in Japan. The pioneering work by Professor takashi Hayashi. Neurochem Int 1996;29:225-9
29. During MJ, Spencer DD. Extracellular hippocampal glutamate and spontaneous seizure in the conscious human brain. Lancet 1993;341:1607-10
30. Le DA, Lipton SA. Potential and current use of N-methyl-D-aspartate (NMDA receptor antagonists in diseases of aging. Drugs Aging 2001;18:717-24
31. Rogawski MA. Revisiting AMPA receptors as an antiepileptic drug target. Epilepsy Curr 2011;11:56-63
32. Plosker GL. Perampanel as adjunctive therapy in patients with partial onset seizures. CNS Drugs 2012;26:1085-96
33. Meldrum BS. Implications for neuroprotective treatments. Prog Brain Res 2002;135:487-95
34. Frandsen A, Schousboe A. AMPA receptor-mediated neurotoxicity: Role of Ca2+ and desensitization. Neurochem Res 2003;28:1495-9
35. Krauss GL, Bar M, Biton V, et al. Tolerability and safety of perampanel: Two randomized dose-escalation studies. Acta Neurol Scand 2012;125:8-15
36. Krauss RI, Bar M, Biton V, et al. Perampanel study 207: Long-term openlabel evaluation in patients with epilepsy. Acta Neurol Scand 2012;126:263-9
37. French JA, Krauss GL, Biton V, et al. Adjunctive perampanel for refractory partial-onset seizures: Randomized phase III study 304. Neurology 2012;79:589-96
38. French JA, Krauss GL, Steinhoff BJ, et al. Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: Results of randomized global phase III study 305 Epilepsia 2013;54:117-25
39. Krauss GL, Serratosa JM, Villanueva V. Adjunctive perampanel for refractory partial-onset seizures: Randomized phase III study 306. Neurology 2012;78:1408-15
40. Krauss GL, Perucca E, Ben-Menachem E, et al. Perampanel, a selective, noncompetitive alpha-amino-3- hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist, as adjunctive therapy for refractory partial-onset seizures: Interim results from phase III, extension study 307. Epilepsia 2013;54:126-34
41. Serratosa JM, Villanueva V, Kerling F, et al. Safety and tolerability of perampanel: A review of clinical trial data. Acta Neurol Scand 2013;127(Suppl 197):30-5
42. Comprehensive summary of safety data from Phase II and III trials of perampanel, including ongoing extension trials. 42. Eisai, Inc. Perampanel (Fycompa) package insert. Woodcliff Lake, NJ: 2012